Prognostic Disclosure Associated With Improved Understanding of End-of-Life Care
the ONA take:
A multicenter observational study sought to determine how prognostic conversations influence perception of life expectancy, distress, and the patient-physician relationship among patients with advanced cancer.
The study included a cohort of 590 patients with advanced cancer who were asked whether their oncologist disclosed an estimate of prognosis.
They were also asked to estimate their own life expectancy and complete assessments of the patient-physician relationship, distress, advance directives, and end-of-life care preferences.
The researchers found that 71% of patients wanted to know their life expectancy, but only 17.6% recalled their physician disclosing a prognosis; 51% were willing to estimate their own life expectancy.
Those patients who recalled a prognostic disclosure provided more realistic estimates of life expectancy compared with those who did not. In addition, their estimates were less likely to differ from their actual survival.
Patients who recalled prognostic disclosure provided an estimated life expectancy that was decreased by 17.2 months compared with those who did not recall prognostic disclosure.
Longer self-estimates of life expectancy were associated with lower likelihood of do-not-resuscitate orders and preference for life-prolonging over comfort-oriented care.
Prognostic disclosure was not associated with worse patient-physician relationship ratings, and sadness or anxiety were not increased in these patients.
How prognostic conversations influence perception of life expectancy, distress, and the patient-physician relationship among patients with advanced cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|